FY2025 EPS Estimates for DNTH Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Dianthus Therapeutics from ($3.45) to ($3.53), while the consensus estimate is set at ($2.61) per share.
• Despite the EPS cut, seven investment analysts currently maintain a "buy" rating on Dianthus Therapeutics, with a consensus price target of $53.00.
• The company's most recent quarterly earnings report revealed a loss of ($0.88) EPS, missing analyst expectations by $0.02 and signaling a challenging financial outlook.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Dianthus Therapeutics in a report issued on Monday, August 11th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($3.53) for the year, down from their previous forecast of ($3.45). The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Cantor Fitzgerald also issued estimates for Dianthus Therapeutics' FY2026 earnings at ($4.06) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. William Blair initiated coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Finally, Robert W. Baird cut their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $19.90 on Wednesday. The firm has a market cap of $640.54 million, a P/E ratio of -6.12 and a beta of 1.43. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $32.27. The firm's 50-day simple moving average is $19.37 and its 200-day simple moving average is $20.01.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock worth $96,776,000 after purchasing an additional 36,133 shares during the period. RA Capital Management L.P. boosted its holdings in Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the period. Octagon Capital Advisors LP lifted its stake in Dianthus Therapeutics by 11.0% in the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after buying an additional 231,500 shares during the last quarter. Vestal Point Capital LP boosted its holdings in shares of Dianthus Therapeutics by 58.1% during the first quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company's stock valued at $30,839,000 after acquiring an additional 625,069 shares during the period. Finally, TCG Crossover Management LLC acquired a new position in shares of Dianthus Therapeutics during the fourth quarter valued at $32,735,000. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.